Abrams PH, Shah PJR, Stone AR, Choa RG (1982) Bladder outflow obstruction treated with phenoxybenzamine. British Journal of Urology, 54, 527-530.
Abrams P, Schulman C, Vaage S and the European Tamsulosin Study Group (1995) Tamsulosin for symptomatic BPH. British Journal of Urology, 76, 325-336.
Alquist RP (1948) Astudy of the adrenotropic receptors. American Journal of Physiology, 153, 586-600.
Andersen JT, Ekman P, Wolf H, Beisland HO, Johansson JE, Kontturi M, Lehtoren T, Tveter K and the Scandinavian BPH Study Group (1995) Can finasteride reverse the progress of BPH? A two-year placebo-controlled study. Urology, 46, 631-637.
Anderson KM, Liao S (1968) Selective retention of dihydrotestosterone by prostate nuclei. Nature, 219, 277-279.
Ball AJ. Fenely RCL, Abrams P (1981) The natural history of untreated prostatism. British Journal of Urology, 53, 613-616.
Bartsch G, Frick J, Ruegg I, Bucher M, Holliger O, Oberholzer M, Rohr HP (1979) Electron microscopic stereological analysis of the human prostate and of benign prostatic hyperplasia. Journal of Urology, 122, 481-486.
Berges RR, Windeler J, Trampisch HJ, Sense TH and the Beta-Sitosterol Study Group (1995) Randomized, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Lancet, 345, 1529-1532.
Boreham PF, Braithwaite P, Milewski P, Pearsdn H (1977) Alpha-adrenergic blockers in prostatism. British Journal of Surgery, 64, 756-757.
Bosch RJ, Griffiths DJ, Blom J, Schroeder FH (1989) Treatment of benign prostatic hyperplasia by androgen deprivation : effects on prostate size and urodynamic parameters. Journal of Urology, 141, 68-72.
Boyarsky S, Jones G, Paulson DF, Prout GR (1977) A new look at bladder neck obstruction by the Food and Drug Administration regulators : guidelines for investigation of benign prostatic hypertrophy, Transactions of the American Association of Genitourinary Surgeons, 68, 29-32.
Boyle P, Gould AL, Roehrhom CG (1996) Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride : meta-analysis of randomised clinical trials. Urology, 48, 398-405,
Brawer M, Epstein H, Adams G, Henry D, Clifton G (1992) Efficacy and safety of terazosin in patients with symptoms of benign prostatic hyperplasia : a new double-blind study. Journal of Urology, 147, 365A.
Brooks JR, Baptista EM, Berman C, Ham EA, Hutchins M, Johnson D, Prumka R, Rasmusson GH, Reynolds GF, Schmitt S, Arth GE (1981) Response of rat ventral prostate to a new and novel 5-alpha-reductase inhibitor. Endocrinology, 109, 830-836.
Brooks JR, Berman D, Glitza MS, Gordon LR, Prumka RL, Reynolds GF, Rasmusson GH (1982) Effect of a new 5-alpha-reductase inhibitor on size, histological characteristics and androgen concentrations of the canine prostate. The Prostate, 3, 35-44.
Bruchovsky N, Wilson JD (1968) The conversion of testosterone to 5-alpha-adrostan-17-beta-ol-3-one by rate prostate in vitro and in vivo. Journal of Biological Chemistry, 243, 2012-2021.
Buzelin JM, Herbert M, Blondin P and the PRAZALF Group (1993) Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia : a comparative study with prazosin. Bnitish Journal of Urology, 72, 992-997.
Cabot AT (1896) The question of castration for enlarged prostate. Annals of Surgery, 24, 265-309.
Caine M. Perlberg S, Gordon R (1975a) The treatment of benign prostatic hypertrophy with flutamide (SCH 13521) : a placebo controlled study. Journal of Urology, 114, 564-568.
Caine M, Raz S. Zeigler M (1975b) Adrenergic and cholinergic receptors in the human prostate. prostatic capsule and bladder neck. British Journal of Urology, 47, 193-202.
Caine M, Pfau A, Perlberg S (1976) The use of alpha-adrenergic blockers in benign prostatic obstruction. British Journal of Urology, 48, 255-259.
Cainc M, Perlberg S (1977) Dynamics of acute retention in prostatic patients and role of adrenergic receptors. Urology, 9, 399-403.
Caine M, Perlberg S, Meretyk S (1978) A placebo controlled trial of the effect of phenoxybenzamine in benign prostatic obstruction. British Journal of Urology, 50, 551-554,
Caine M, Perlberg S, Shapiro A (1980) Phenoxybenzamine for benign prostatic obstruction. Urology, 17, 542-546.
Caine M (1986) The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. Journal of Urology, 136, 1-4.
Caine M (1988) Alpha-adrenergic mechanisms in dynamics of benign prostatic hypertrophy. Urology, 32 (Suppl.), 16-20.
Carbin BE, Larsson B, Lindahl O (1990) Treatment of benign prostatic hyperplasia with phytosterols. British Journal of Urology, 66, 639-641.
Champault G, Patel JC, Bonnard AM (1984) A double-blind trial of an extract of the plant Serenoa repens in benign prostatichyperplasia. British Journal of Clinical Pharmacology, 18, 461-462.
Chapple CR, Christmas TJ, Miiroy EJG (1990) A twelve week placebo-controlled study of prazosin in the treatment of prostatic obstruction. Urologia Internationalis, 45, 47-55.
Chapple CR, Carter P, Christmas TJ, Noble JG, Kirby RS,. Abrams P, Milroy EJG (1991) A three month double-blind placebo-controlled trial of doxazosin as a treatment for benign prostatic hyperplasia obstruction. Neurourology and Urodynamics, 10, 298-299.
Chow W, Hahn D, Sandhu D, Slaney P, Henshaw R, Das G, Wells P (1990) Multicentre controlled trial of indoramin in the symptomatic relief of benign prostatic hypertrophy. British Journal of Urology, 65, 36-38.
Christensen MM, Bendix Hollne J, Rasmussen PC, Jacobsen F, Nielsen J. Norgaard JP, Olesen S, Noer I, Wolf H, Husted SE (1993) Doxazosin treatment in patients with prostatic obstruction. A double-blind, placebo-controlled study. Scandinavian Journal of Urology and Nephrology, 27, 39-44.
Dreikorn K, Richter R (1989) Conservative nonhormonal treatment of patients with benign prostatic hyperplasia. In : Prostatic Hyperplasia, pp. 109-121. Edited by Ackermann R and Scroder FH. Berlin, Walter de Gruyter.
Dunzendorfer U, Jonas D. Weber W (1976) The autonomic innervation of the human prostate. Histochemistry of acetyl-cholinesterase in the normal and pathological state. Urological Research, 4, 29-31.
Dunzendorfer U (1988) Clinical experience : symptomatic management of BPH with terazosin. Urology, 32 (Suppl.). 27-31.
Eri LM, Tveter KJ (1995) Alpha blockade in the treatment of symptomatic benign prostatic hyperplasia. Journal of Urology, 154. 923-934.
Fabricius PG, weizert P, Dunzendorfer U, MacHannaford JM, Maurath C (1990) Efficacy of once-a-day terazosin in benign prostatic hyperplasia : a randomized. double-blind, placebo-controlled clinical trial. Prostate. 3, 85-93.
Fair WR, Presti JC, Sogani P, Andriole G, Seidmon J, Fergusson D, Gormley GJ (1991) Multicentre, randomized double-blind placebo-controlled study to investigate the effect of finasteride (MW 906) on stage D prostate cancer. Journal of Urology, 145, 317A.
Farnsworth WE. Brown JR (1963) Testosterone metabolism in the prostate. National Cancer Institute Monographs, 12, 323-325.
Farrar DJ, Pryor JS (1976) The effect of bromocriptine in patients with benign prostatic hypertrophy. British Journal of Urology, 48, 73-75.
Fawzy A, Braun K, Lewis GP, Gaffrey M, Ice K, Dias N (1995) Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients : a multicenter study. Journal of Urology, 154, 105-109.
Finasteride Study Group (1993) Finasteride (MK906) in the treatment of benign prostatic hyperplasia. Prostate, 22, 291-299.
Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G (1995) Use of recombinant α1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. European Journal of Pharmacology, 288, 201-207.
Furuya S, Kumamoto Y, Yokoyama E, Tsukamoto T, Izumi T, Abiko Y (1982) Alpha-adrenergic tlctivity and urethral pressure in prostatic zone in benign prostatic hypertrophy. Journal of Urology, 128, 836-839.
Gee WF, Holtgrewe HL, Albertsen PC, Litwin MS, Manyat MJ, O'Leary MP, Painter MR (1995) Practice trends in the diagnosis and management of benign prostatic hyperplasia in the United States. Journal of Urology, 154, 205-206.
Geller J, Bora R, Roberts T, Newman H, Lin A. Silva R (1965) The treatment of benign prostatic hypertrophy and hypoxyprogesterone caproate. Effect on clinical symptoms. morphology alld endocrine function. Journal of the American Medical Association, 193, 121-128.
Gilberti C, Damonte P, Michelotti P, Martorana G (1984) The effect of thymoxamine in benign prostatic hypertrophy : a double-blind cross-over study. IRCS Medical Science, 12, 591.
Gillenwater JY, Conn RL, Chrysant SG, Roy J, Gaffrey M, Ice K, Dias N (1995) Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate hypertension : a double-blind, placebo-controlled, dose-response multicentre study. Journal of Urology, 154, 110-115.
Gingell JC, Knonagel H, Kurth KH, Tunn UW (1995) Placebo controued double-blind study to test the efficacy of the aromatase inhibitor atamestane in patients with benign prostatic hyperplasia not requiring operation. Journal of Urology, 154, 399-401.
Gklyama T, Yachika S, Iguchi M, Kohri K, Kenoka S< Matsuura T, Nagai N, Kurita T (1983) Clinical studies. uroflowmetric and ultrasonography evaluation of oxendolon on benign prostatic hypertrophy. Acta Urologica of Japan, 25, 535-536.
Gormley GJ, Stoner E, Bruskevitz RC and the Finasteride Study Group (1992) The effect of finasteride in men with benign prostatic hyperplasia. New England Journal of Medicine, 327, 1185-1191.
Guess HA, Jacobsen SJ, Girman CJ, Oesterling JE, Chute CG, Panser LA, Lieber MM (1995) The role of community-based longitudinal studies in evaluating treatment effects-example : benign prostatic hyperplasia. Medical Care, 33 (4), 26-35.
Hansen BJ, Nordhng J, Mensink HJA (1993) Alfuzosin in the treatment of benign prostatic hyperplasia : effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. Scandinavian Journal of Urology and Nephrology, 157, 169-176.
Hedlund H, Andersson KE, Ek A (1983) Effect of prazosin in patients with benign prostatic obstruction. Journal of Urology, 130, 275-278.
Hedhlnd H, Andersson KE, Larsson B (1985) Alpha receptors and muscarinic receptors in the isolated human prostate. Journal of Urology, 134, 1291-1298.
Hedlund H, Andersson KE (1988) Effects of prazosin and carbachol in patients with benign prostatic hypertrophy. Scandinavian Journal of Urology and Nephrology, 22, 19-22.
Horby-Petersen J, Schmidt PF, Meyhoff HH, Frimoldt-Moller C, Mathiesen FR (1985) The effects of a new serotonin receptor antagonist (ketanserin) on the lower urinary tract function, in patients with prostatism. Journal of Urotogy, 133, 1095-1098.
Huggins C, Stevens RA (1940) The effect of castration on benign hypertrophy of the prostate in man. Journal of Urology, 43, 705-714.
Iacovou JW, Dunn M (1987) Indoramin-an effective new drug in the management of bladder outflow obstruction. British Journal of Urology, 60, 526-528.
Imperato-McGinley J, Guevro L, Gauteri T and Petersen RE (1974) Steroid 5-alpha-reductase deficiency in man : an inherited form of pseudohermaphroditism. Science, 186, 1213-1215.
Jardin A, Bensadounm H, Delauche-Cavallier MC, Attali P (1991) Alfuzosin f or treatment of benign prostatic hypertrophy. Lancet, 337, 457-461.
Jardin A, Bensadoun H, Delauche-Cavallier MC, Stalla-Bourdillon A, Attali P and BPH ALF group (1994) Long term treatment of benign prostatic hyperplasia with alfuzosin : a 24-30 month study. Bnitish Journal of Urology, 74, 579-584.
Jensen D (1981) Uninhibited neurogenic bladder treated with prazosin. Scandinavian Journal Urology and Nephrology, 15, 229-233.
Kaufman J. Goodwin W E (1959) Hormonal management of the benign obstructing prostate : use of combined androgen-oestrdgen therapy. Journal of Urology, 81, 165-171.
Kawabe K, Ueno A, Takimoto Y, Aso Y, Kato H (1990) Use of an alpha-1 blocker, YM 617, in the treatment of benign prostatic hypertrophy. Journal of Urology, 144, 908-912.
Kirby RS, Coppinger SWC, Corcoran MO, Chapple CR, Flannigan M, Milroy EJG (1987) Prazosin in the treatment of prostatic obstruction. A placebo controlled study. British Journal of Urology, 60, 136-142.
Kirby RS, Eardley J, Bryan J, Vale JA, Miller PD, Christmas TJ, Liu S (1991) A urodynamic study of a 5-alpha-reductase inhibitor in the treatment of infravesical obstruction due to BPH. Neurology and Urodynamics, 10, 300-301.
Kirby RS, Bryan J, Christmas TJ, Vale J, Eardley I, Webb J (1992) Finasteride in the management of benign prostate hyperplasia-a urodynamic study. Bnitish Journal of Urology, 70, 65-72.
Kirby RS, Vale J, Bryan J, Holmes K, Webb JAW (1993) Long-term urodynamic effects of finasteride in benign prostatic hyperplasia : a pilot study. European Urology, 24, 20-26.
Kirby RS (1995a) Efficacy of doxazosin in nolmotensive and hypertensive patients with benign prostatic hyperplasia. Scandinavian Journal of Urology and Nephrology, 29, 29-33.
Kirby RS (1995b) Doxazosin in benign prostatic hyperplasia : effects on blood pressure and urinary flow in normotensive and hypertensive men. Urology, 46, 182-186.
Kleeman FJ (1970) The physiology of the internal urinary sphincter. Journal of Urology, 104, 549-552.
Krane RJ. Olsson CA (1973) Phenoxybenzamine in neurogenic bladder dysfunction. I. A theory of micturition. Journal of Urology, 110, 650-652.
Langer SZ (1974) Presynaptic regulation of noradrenaline release. Biochemical Pharmacology, 23, 1793-1798.
Lepor H, Shapiro E (1984) Characterization of alpha-1 adrenergic receptors in human benign prostatic hyperplasia. Journal of Urology, 132, 1226-1229.
Lepor H, Gup DL Bauman M, Shapiro E (1988) Laboratory assessment of terazosion and alpha-1blockade in prostatic hyperplasia. Urology, 32 (Suppl.), 21-26.
Lepor H, Knapp-Maloney G, Sunshine H (1990) A dose titration study evaluating terazosin, a selective, once-a-day alpha-1 blocker for the treatment of symptomatic benign prostatic hyperplasia. Journal of Urology, 144, 1393-1397.
Lepor H, Machi G (1992) The relative efficacy of terazosin versus terazosin and flutamide tot the treatment of symptomatic BPH. Prostate, 20, 89-93.
Lepor H, Soloway M, Klilnberg IW, Drago JR, Narayan P, Laddu A, Maurath C (1992) Long term safety and efficacy of terazosin, a selective alpha-1 blocker, in patients with benign prostatic hyperplasia (BPH). Journal of Urology, 147, 365A.
Lepor H d 995) Long-term efficacy and safety ofterazosin in patients with benign prostatic hyperplasia. Urology, 45, 406-413.
Lepor H, Williford WO, Barry MJ, Brawen MK. Dixon CM, Gormley G, Maakenson C, Machi M, Narayan P, Padley RV (1996) The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia. New Eng J Med, 335, 533-539.
Leventhal A, Pfau A (1978) Pharmacologic management of post-operative overdistension of the bladder. Surgery, Gynaecology and Obstetrics, 146, 347-349.
Lukacs B, McCarthy C, Grange JC and the QoL BPH Study Group (1993) Long-term quality of life in patients with benign prostatic hypertrophy : preliminary results of a cohort study of 7093 patients treated with the alpha-1 adrenergic blocker alfuzosin. European Urology, 24, 34-40.
Madsen PO, Dorflinger T, Frimoldt-Moller PC, Jensen KM (1984) Candicidin in treatment of benign prostatic hypertrophy. Journal of Urology, 132, 1235-1238.
Malone PR, Cook A, Edmondson R, Gill MW, Shearer RJ (1988) Prostatectomy : patients' perception and long-term follow-up. British Journal of Urology, 61, 234-238.
Martorana G, Gilberti C, Damonte P, Ciprandi G, Direnzio W, Giuliani L (1984) The effect of prazosin in benign prostatic hypertrophy, a placebo controlled double-blind study. IRCS Medical Science, 12, 11-12.
Neaton JD, Grimm RH, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, Cutler A, Flack JM, Schoenberger JA, McDonald R, Lewis CE, Liebson PR and the Treatment of Mild Hypertension Study Research Group (1993) Treatment of mild hypertension. Final results. Journal of the American Medical Sssociation, 270, 713-724.
Oesterling JE, Juniewicz PE, Walters JR, Strandberg JD, Steel RE, and Ewing LC (1988) Aromatase inhibition in the dog, Effect on growth, function and pathology of the prostate. Journal of Urology, 139, 832-839.
Peirson EL (1946) A study of the effect of stilboestrol therapy on the size of the benignly enlarged prostate gland. Journal of Urology, 55, 73-78.
Perlberg S, Caine M (1977) Dynamics of acute retention in prostatic patients and role of adrenergic receptors. Urology, 9, 399-403.
Pool JL (1991) Effects of doxazosin on serum lipids : a review of the clinical data and molecular basis for altered lipid metabolism. American Heart Journal, 121, 251-262.
Pool JL (1994) Effects of doxazosin on serum lipids : a review of the clinical data and molecular basis for altered lipid metabolism. Journal of Clinical Practice, 74, 8-12.
Ramsay JWA, Scott GI, Whitfield HN (1985) A double blind controlled trial of a new alpha-1 blocking drug in the treatment of bladder outfiow obstruction. British Journal of Urology, 57, 657-659.
Rasmusson GH, Reynolds GF, Utre T, Jobson RB, Prumka RL, Berman C, Brooks JR (1984) Azasteroids as nhibitors of rat prostatic 5-alpha-reductase. Journal of Medical Chemistry, 27, 1690-1701.
Reece-Smith H, Memon A, Smart CJ, Dewbury K (1986) The value of permixion in benign prostatic hypertrophy. British Journal of Urology, 58, 36-40.
Rhodes L, Primika RL, Berman C, Vergult G, Gabriel M, Pierre-Malice M, Gibelin B (1993) Comparison of finasteride (Proscar) a 5 alpha-reductase inhibitor with various commercial plant estracts and in vivo and in vitro 5 alpha-reductase inhibitor. Prostate, 22, 43-51.
Ronchi F, Margonato A, Ceccardi R, Rigatti P, Rossini BM (1982) Symptomatic treatment of benign prostatic obstruction with nicergoline : a placebo-controlled clinical study and urodynamic evaluation. Urological Research, 1O, 131-134.
Rossi MA, Carillo SV (1985) Does norepinephrine play a central causative role in the process of cardiac hypertrophy? American Heart Journal, 100, 622-624.
Ruffolo RR, Nichols AJ, Stadel JM, Hieble P (1991) Structure and function of alpha-adrenoceptors. Pharmacologica Reviews, 43, 475-501.
Schulze H, Barrack ER (1987) Immunocytochemical localization of oestrogen receptors in spontaneous and experimentally induced canine BPH. Prostate, 11, 145-162.
Scott WW, Wade JC (1969) Medical treatment of benign nodular prostatic hyperplasia with cyproterone acetate. Journal of Urology, 101, 81-85.
Shapiro E, Mazouz B, Caine M (1981) The alpha adrenergic effect of prazosin on the human prostate. Urological Research, 9, 17-20.
Siroky MB, Olsson CA, Krane RJ (1979) The flow rate nomogram : I. Development. Journal of Urology, 122, 665-668.
Stenger A, Tarayre JP, Cavilla E, Delhon A, Charveron M, Morre M, Lauressergues H (1982) Etude pharmatologique et biochemique de l'extrait hexanique de Serenoa repens B. Gazette Medical de France, 89, 2041-2048.
Stodt MA, Abrams (1991) Indoramin in the treatment of prostatic bladder outflow obstruction. British Journal of Urology, 67, 499-501.
Stone NN, Fair WR, Fishman J (1986) Oestrogen formation in human prostate tissue from patients with and without BPH. Prostate, 9, 311-318.
Stone N, Cleian S, Ray PS (1989a) A double-blind randomized controlled study of the effect of flutamide on benign prostatic hypertrophy : side effects and hormonal changes. Journal of Urology, 141, 307A.
Stone N, Ray PS, Smith JA (1989b) A double-blind radiological controlled study of the effect of flutamide on benign prostatic hypertrophy-clinical efficacy. Journal of Urology, 141, 240A.
Stoner E (1990) The clinical development of a 5-alpha-reductase inhibitor, finasteride. Journal of Steroid Biochemistr y and Molecular Biology, 37, 375-378.
Stoner E (1992) The clinical effects of a 5-alpha-rductase inhibitor, finasteride, on benign prostatic hyperplasia. Journal of Urology, 147, 1298-1302.
Stoner E and the Finasteride Study Group (1994) Three year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology, 43, 284-294.
Sultan C, Terraza A, Devillier C, Cavilla E, Briley M, Loire C, Descomps B (1984) Inhibition of androgen metabolism and binding by a liposterolic extract of Serenoa repens B in human foreskin fibroblasta. Journal of Steroid Biochemistry, 20, 515-519.
Tammela TLJ, Kontturi MJ (1993) Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia. Journal of Urology, 149, 342-344.
Teillac P, Delauche-Cavalier MC, Attali P (1992) Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. British Journal of Urology, 70, 58-64.
Tunn UW, Schweikurt HU (1989) Aromatase : inhibitors in the management of benign prostatic hyperplasia. In : New Developments in Biosciences 5. Prostatic Hyperplasia, pp. 139-149. Berlin, WaIter de Gruyter.
Vermeulen A, Giagulli VA, Scheppe P, Buntinx A, Stoner E (1989) Hormonal effects of an orally active 4-azasteroid inhibitor of 5-alpha-reductase in humans. The Prostate, 14, 45-53.
Whitfield HN, Doyle PT, Mayo ME, Poopalasingham N (1976) The effect of adrenergic blocking drugs on outflow resistance. British Journal of Urology, 47, 823-827.
Wolf H, Madsen P (1968) Treatment of benign prostatic hypertrophy with progestational agents : a preliminary report. Journal of Urology, 99, 790-85.
Yazawa H, Honda K (1993). Alpha1-adrenoceptor subtype in the rat prostate is preferentiauy the alpha1A subtype. Japanese Journal of pharmacology, 62, 297-304.